Abstract
The last few years have seen the identification of numerous small molecules that selectively inhibit specific class I isoforms of PI3K (phosphoinositide 3-kinase), yet little has been revealed about the molecular basis for the observed selectivities. Using site-directed mutagenesis, we have investigated one of the areas postulated as being critical to the observed selectivity. The residues Thr(886) and Lys(890) of the PI3Kgamma isoform project towards the ATP-binding pocket at the entrance to the catalytic site, but are not conserved. We have made reciprocal mutations between those residues in the beta isoform (Glu(858) and Asp(862)) and those in the alpha isoform (His(855) and Gln(859)) and evaluated the potency of a range of reported PI3K inhibitors. The results show that the potencies of beta-selective inhibitors TGX221 and TGX286 are unaffected by this change. In contrast, close analogues of these compounds, particularly the alpha-isoform-selective compound (III), are markedly influenced by the point mutations. The collected data suggests two distinct binding poses for these inhibitor classes, one of which is associated with potent PI3Kbeta activity and is not associated with the mutated residues, and a second that, in accord with earlier hypotheses, does involve this pair of non-conserved amino acids at the catalytic site entrance and contributes to the alpha-isoform-selectivity of the compounds studied.
MeSH Terms
Binding Sites
Catalysis
Catalytic Domain
Enzyme Inhibitors/chemistry,pharmacology
Kinetics
Mutagenesis, Site-Directed
Phosphatidylinositol 3-Kinases/chemistry,genetics
Phosphoinositide-3 Kinase Inhibitors
Protein Isoforms/antagonists & inhibitors,chemistry,metabolism
Structure-Activity Relationship
Substrate Specificity
Chemicals
Enzyme Inhibitors
Phosphoinositide-3 Kinase Inhibitors
Protein Isoforms
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Frazzetto Mark
Australian Centre for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia.
Suphioglu Cenk
Zhu Jiuxiang
Schmidt-Kittler Oleg
Jennings Ian G
Cranmer Susan L
Jackson Shaun P
Kinzler Kenneth W
Vogelstein Bert
Thompson Philip E
References (20)
20 references, click to expand
-
Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine.
Mol Cell. 2000 Oct;6(4):909-19
PMID: 11090628
-
Class I phosphoinositide 3-kinases.
Int J Biochem Cell Biol. 2003 Jul;35(7):1028-33
PMID: 12672472
-
Oncogenic mutations of PIK3CA in human cancers.
Cell Cycle. 2004 Oct;3(10):1221-4
PMID: 15467468
-
Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment.
Biochem Soc Trans. 2004 Apr;32(Pt 2):393-6
PMID: 15046615
-
Study on improving the selectivity of compounds that inhibit two PI3Ks (gamma and delta).
J Mol Model. 2006 Mar;12(4):445-52
PMID: 16404616
-
In vitro and in vivo inhibition of rat vascular smooth muscle cell migration and proliferation by a 2-aminochromone U-86983.
J Pharmacol Exp Ther. 1994 Oct;271(1):415-21
PMID: 7965742
-
PI3Kgamma inhibition: towards an 'aspirin of the 21st century'?
Nat Rev Drug Discov. 2006 Nov;5(11):903-18
PMID: 17080027
-
Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
Nat Med. 2005 Sep;11(9):936-43
PMID: 16127437
-
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold.
Bioorg Med Chem. 2004 Sep 1;12(17):4749-59
PMID: 15358300
-
Synthesis and function of 3-phosphorylated inositol lipids.
Annu Rev Biochem. 2001;70:535-602
PMID: 11395417
-
Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit.
Mol Cell Biol. 1998 Mar;18(3):1379-87
PMID: 9488453
-
Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.
Annu Rev Cell Dev Biol. 2001;17:615-75
PMID: 11687500
-
Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation.
Science. 2000 Feb 11;287(5455):1049-53
PMID: 10669418
-
PI 3-kinase p110beta: a new target for antithrombotic therapy.
Nat Med. 2005 May;11(5):507-14
PMID: 15834429
-
Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors.
Bioorg Med Chem. 2006 Oct 15;14(20):6847-58
PMID: 16837202
-
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
Science. 2007 Dec 14;318(5857):1744-8
PMID: 18079394
-
Selective role of PI3K delta in neutrophil inflammatory responses.
Biochem Biophys Res Commun. 2003 Sep 5;308(4):764-9
PMID: 12927784
-
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.
Cell. 2006 May 19;125(4):733-47
PMID: 16647110
-
Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
J Med Chem. 2006 Jun 29;49(13):3857-71
PMID: 16789742
-
Phosphoinositide 3-kinases as drug targets in cancer.
Curr Opin Pharmacol. 2005 Aug;5(4):357-65
PMID: 15963759